tiprankstipranks
Advertisement
Advertisement

URGN Stock Latest News

UroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
RatingsUroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
5d ago
URGN
UroGen, Teva Settle Jelmyto Patent Dispute, License Generic
PremiumCompany Announcements
UroGen, Teva Settle Jelmyto Patent Dispute, License Generic
6d ago
8K
URGN
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
PremiumCompany Announcements
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
20d ago
URGN
UroGen Pharma: Buy Rating Reiterated as Strong ZUSDURI Data and UGN-103 Pipeline Support Unchanged $45 Price Target
PremiumRatings
UroGen Pharma: Buy Rating Reiterated as Strong ZUSDURI Data and UGN-103 Pipeline Support Unchanged $45 Price Target
22d ago
URGN
UroGen Pharma reports month results from UTOPIA trial
PremiumThe Fly
UroGen Pharma reports month results from UTOPIA trial
24d ago
URGN
UroGen Pharma presents 36-month ENVISION trial data
PremiumThe FlyUroGen Pharma presents 36-month ENVISION trial data
26d ago
URGN
UroGen Pharma assumed with a Buy at Ladenburg
Premium
The Fly
UroGen Pharma assumed with a Buy at Ladenburg
28d ago
URGN
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
Premium
The Fly
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
29d ago
URGN
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
PremiumCompany Announcements
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
1M ago
URGN
UroGen Pharma price target raised to $40 from $34 at Oppenheimer
PremiumThe Fly
UroGen Pharma price target raised to $40 from $34 at Oppenheimer
1M ago
URGN
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
PremiumThe Fly
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
1M ago
URGN
Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
PremiumRatings
Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
1M ago
URGN
UroGen Pharma: Undervalued Chemoablative Disruptor in NMIBC With Blockbuster Potential by 2030
PremiumRatingsUroGen Pharma: Undervalued Chemoablative Disruptor in NMIBC With Blockbuster Potential by 2030
2M ago
URGN
UroGen Pharma initiated with a Buy at Jefferies
Premium
The Fly
UroGen Pharma initiated with a Buy at Jefferies
2M ago
URGN
UroGen Pharma publishes results from ENVISION trial of Zusduri
Premium
The Fly
UroGen Pharma publishes results from ENVISION trial of Zusduri
2M ago
URGN
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
PremiumThe Fly
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
3M ago
URGN
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
PremiumRatings
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
3M ago
URGN
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
PremiumCompany Announcements
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
3M ago
URGN
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
PremiumRatings
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
3M ago
URGN
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
PremiumCompany AnnouncementsTrade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
3M ago
URGN
UroGen Pharma Secures New $250 Million Term Loan
Premium
Company Announcements
UroGen Pharma Secures New $250 Million Term Loan
3M ago
8K
URGN
UroGen Pharma reports Q4 EPS (54c), consensus (51c)
Premium
The Fly
UroGen Pharma reports Q4 EPS (54c), consensus (51c)
3M ago
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >